Oncode Institute spin-off Omivera, built around the CellEKT chemical proteomics platform, has secured a seed investment from UNIIQ, an investment fund focused on the proof-of-concept phase, aiming to bring innovations to the market faster. 

Cancer research often advances through ideas that are complex, and require sustained effort over time - driven by people with a strong sense of purpose. In this interview, Madelon Maurice, professor of molecular cell biology at University Medical Centre Utrecht (UMC Utrecht) and Oncode Institute investigator, and Maureen Spit, Vice President of Research at Laigo Bio, reflect on what motivates them as scientists and why they chose to focus on one of the most persistent challenges in oncology: how to target cancer-driving proteins that remain beyond the reach of current therapies.

The Alpe d’HuZes/KWF Fund will invest €4.5 million in Oncode Institute over the next two years. Made possible by the participants of Alpe d’HuZes, this funding accelerates innovative cancer research and enables promising ideas to more quickly develop into applications for patients. The investment supports multiple innovative research projects and aligns with the Alpe d’HuZes research themes: understanding, detection, and cure.

A novel cancer treatment strategy that enables the targeted degradation of membrane proteins has received funding from the highly competitive European Innovation Council Pathfinder programme. The OutMARCH project aims to make previously “undruggable” cancer proteins accessible, potentially offering new ways to overcome resistance to existing therapies.

The Lead4Life research programme has been awarded a €5 million public–private partnership (PPP) grant from Health~Holland for the development of lead-212–based radiopharmaceuticals for the treatment of cancer. 

Some scientific breakthroughs don’t belong to a single lab, discipline, or idea. They only become possible when collaboration is the strategy. Oncode Institute brought seven Oncode Investigators together across biology, AI, and clinical research to create PARM – a new method to break the limits of traditional genomic computing. This enabled them  to reveal the language for genetic instructions that tell genes when to turn on and off. 

On World Cancer Day, we bring together three people connected by a shared mission. Gerrit Oostenveld is a melanoma survivor and dedicated Patient Partner. Myrthe Jager and Joske Ubels are Oncode Researchers. What unites them is a belief that cancer research is strongest when scientists and patients work side by side.

More than 70 patient partners, patient organisations and Oncode researchers took part in the fifth edition of Oncode Institute’s Patient Perspective Programme Annual Meeting in Utrecht. The day created room for exchange, reflection and discussion on how experience and research can reinforce each other.

What if you could know, within days, whether a cancer treatment will actually work for a patient? For thousands of women diagnosed with ovarian cancer each year, that question is painfully urgent.  Cytoreductive surgery combined Platinum-based chemotherapy is still the standard first-line treatment, yet for nearly half of all patients it offers little benefit. Instead, it brings heavy side effects, delays effective care, and allows the disease to return in a more aggressive form.

Blocking a newly discovered immune pathway enables microglia to control diffuse midline glioma, laying the groundwork for a future therapeutic strategy. Researchers have identified a powerful new way to fight diffuse midline glioma (DMG), one of the most aggressive and lethal pediatric brain tumors in preclinical laboratory models. 

Cyclomics BV, a pioneer in liquid biopsy technology, announces the successful closing of a new investment round led by Myosotis Investments and supported by Oncode Bridge Fund. This capital infusion marks a pivotal transition for the company as it expands its commercial operations to bring innovative diagnostic products to cancer patients.

Researchers at Oncode Institute and Princess Máxima Center have developed a new human model of the brainstem that is changing how one of the most aggressive childhood brain cancers can be studied. 

Gisteren hebben KiKa en Oncode Institute een overeenkomst getekend om de komende jaren intensief samen te werken op het gebied van kinderkankeronderzoek.

Oncode Institute accelerates the path from fundamental discovery to patient impact by supporting clinical proof of concept projects that turn scientific insights into diagnostics and therapies.

MRM Health has entered into a strategic research collaboration with Oncode Institute and the Netherlands Cancer Institute (NKI) to accelerate the development of microbiome-based therapies that enhance the effectiveness of cancer immunotherapy. 

Researchers have discovered a way to extend the effectiveness of hormone therapy using a safe, inexpensive, and widely used class of drugs: corticosteroids. The new findings, published in Nature, pave the way for a clinical study starting in 2026.